Literature DB >> 25786689

Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes.

Kei Ohnuma1, Ryo Hatano1, Thomas M Aune2, Haruna Otsuka1, Satoshi Iwata1, Nam H Dang3, Taketo Yamada4, Chikao Morimoto5.   

Abstract

Obliterative bronchiolitis is a potentially life-threatening noninfectious pulmonary complication after allogeneic hematopoietic stem cell transplantation and the only pathognomonic manifestation of pulmonary chronic graft-versus-host disease (cGVHD). In the current study, we identified a novel effect of IL-26 on transplant-related obliterative bronchiolitis. Sublethally irradiated NOD/Shi-scidIL2rγ(null) mice transplanted with human umbilical cord blood (HuCB mice) gradually developed clinical signs of graft-versus-host disease (GVHD) such as loss of weight, ruffled fur, and alopecia. Histologically, lung of HuCB mice exhibited obliterative bronchiolitis with increased collagen deposition and predominant infiltration with human IL-26(+)CD26(+)CD4 T cells. Concomitantly, skin manifested fat loss and sclerosis of the reticular dermis in the presence of apoptosis of the basilar keratinocytes, whereas the liver exhibited portal fibrosis and cholestasis. Moreover, although IL-26 is absent from rodents, we showed that IL-26 increased collagen synthesis in fibroblasts and promoted lung fibrosis in a murine GVHD model using IL-26 transgenic mice. In vitro analysis demonstrated a significant increase in IL-26 production by HuCB CD4 T cells following CD26 costimulation, whereas Ig Fc domain fused with the N-terminal of caveolin-1 (Cav-Ig), the ligand for CD26, effectively inhibited production of IL-26. Administration of Cav-Ig before or after onset of GVHD impeded the development of clinical and histologic features of GVHD without interrupting engraftment of donor-derived human cells, with preservation of the graft-versus-leukemia effect. These results therefore provide proof of principle that cGVHD of the lungs is caused in part by IL-26(+)CD26(+)CD4 T cells, and that treatment with Cav-Ig could be beneficial for cGVHD prevention and therapy.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25786689      PMCID: PMC4568737          DOI: 10.4049/jimmunol.1402785

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.

Authors:  B R Blazar; P A Taylor; M W Boyer; A Panoskaltsis-Mortari; J P Allison; D A Vallera
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

Review 2.  The structure and function of CD26 in the T-cell immune response.

Authors:  C Morimoto; S F Schlossman
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

3.  Aberrant CD3- and CD28-mediated signaling events in cord blood T cells are associated with dysfunctional regulation of Fas ligand-mediated cytotoxicity.

Authors:  K Sato; H Nagayama; T A Takahashi
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

4.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.

Authors:  Fumihiko Ishikawa; Masaki Yasukawa; Bonnie Lyons; Shuro Yoshida; Toshihiro Miyamoto; Goichi Yoshimoto; Takeshi Watanabe; Koichi Akashi; Leonard D Shultz; Mine Harada
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

7.  Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.

Authors:  J H Antin; B E Bierer; B R Smith; J Ferrara; E C Guinan; C Sieff; D E Golan; R M Macklis; N J Tarbell; E Lynch
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

8.  Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations.

Authors:  Chunyan Zhang; Ivan Todorov; Zhifang Zhang; Yinping Liu; Fouad Kandeel; Stephen Forman; Samuel Strober; Defu Zeng
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 9.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

Review 10.  Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy.

Authors:  J A Engelman; X Zhang; F Galbiati; D Volonte; F Sotgia; R G Pestell; C Minetti; P E Scherer; T Okamoto; M P Lisanti
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

View more
  16 in total

1.  Increased interleukin-26 expression in proliferative diabetic retinopathy.

Authors:  Peng Wang; Wen-Yan Wang; Xue-Dong Zhang
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

2.  Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis.

Authors:  Ryo Hatano; Takumi Itoh; Haruna Otsuka; Sayo Okamoto; Eriko Komiya; Satoshi Iwata; Thomas M Aune; Nam H Dang; Kyoko Kuwahara-Arai; Kei Ohnuma; Chikao Morimoto
Journal:  MAbs       Date:  2019-08-18       Impact factor: 5.857

3.  Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Authors:  Victor Tkachev; Scott N Furlan; Benjamin Watkins; Daniel J Hunt; Hengqi Betty Zheng; Angela Panoskaltsis-Mortari; Kayla Betz; Melanie Brown; John B Schell; Katie Zeleski; Alison Yu; Ian Kirby; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; Duncan Casson; Phil Bland-Ward; Leslie S Kean
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

Review 4.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

5.  IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.

Authors:  Takumi Itoh; Ryo Hatano; Yoshiya Horimoto; Taketo Yamada; Dan Song; Haruna Otsuka; Yuki Shirakawa; Shuji Mastuoka; Noriaki Iwao; Thomas M Aune; Nam H Dang; Yutaro Kaneko; Ko Okumura; Chikao Morimoto; Kei Ohnuma
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

6.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

7.  Recombinant human IL-26 facilitates the innate immune response to endotoxin in the bronchoalveolar space of mice in vivo.

Authors:  Aihua Bao; Karlhans Fru Che; Steven Bozinovski; Jie Ji; Joshua A Gregory; Susanna Kumlien Georén; Mikael Adner; Lars-Olaf Cardell; Anders Lindén
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 8.  The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Tue W Kragstrup; Thomas Andersen; Line D Heftdal; Malene Hvid; Jens Gerwien; Pallavur Sivakumar; Peter C Taylor; Ladislav Senolt; Bent Deleuran
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 9.  IL-26, a Cytokine With Roles in Extracellular DNA-Induced Inflammation and Microbial Defense.

Authors:  Vincent Larochette; Charline Miot; Caroline Poli; Elodie Beaumont; Philippe Roingeard; Helmut Fickenscher; Pascale Jeannin; Yves Delneste
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

Review 10.  The Interleukin-20 Cytokine Family in Liver Disease.

Authors:  Esther Caparrós; Rubén Francés
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.